All In MedTech

Device Trial Radar · NCT03257436

Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)

Last checked: Nov 19, 2026Latest source record: Jan 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

586

Actual

Start

Jan 5, 2018

Primary completion

Nov 19, 2020

Study completion Nov 19, 2020

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Aug 22, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Prospective, multi-center, single arm, post approval study to be conducted in the United States.

Conditions

  • Left Ventricular Dysfunction

Interventions

  • CRT-DDevice

    Left Ventricular MultiSite Pacing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. LV MSP Feature Related Complication-Free RateTime frame: Between 6 month visit and the 12 month visit in non-responders with LV MSP on for any duration.
  2. Proportion of LV MSP Group Subjects With an Improved Clinical Composite Score at 12 MonthsTime frame: 12 Month Follow Up

Locations

54 sites in 1 country. Site status is shown where the registry gives one.

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Phoenix Cardiovascular Group

    Phoenix, Arizona

  • Cardiology Associates of NEA

    Jonesboro, Arkansas

51 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.